Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 avr. 2026 17h02 HE | Source: Replimune, Inc.

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
10 avr. 2026 16h02 HE | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
10 avr. 2026 08h00 HE | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
09 avr. 2026 16h31 HE | Source: Nouveau Monde Graphite Inc.

NMG Announces US$297 Million Equity Financing Package including US$213 Million Private Placement and US$84 Million Bought Deal Public Offering, Advancing Phase-2 Matawinie Mine toward FID

Canada Growth Fund, the Government of Québec, through Investissement Québec, and Eni S.p.A., commit to an aggregate US$213 million equity investment, to support the advancement of NMG’s Phase-2...
09 avr. 2026 16h05 HE | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of...
09 avr. 2026 16h01 HE | Source: Perpetuals.com Ltd.

Perpetuals.com Launches Strategic Initiative to Deploy Next-Generation Agentic AI Infrastructure Platform for Fintech and Digital Assets Industry; Secures Exclusive License for Proprietary On-Premises Quantitative Research Platform "Forgentiq.ai"

Company positions itself to become a dedicated AI infrastructure partner for the financial technology and digital assets ecosystem, deploying secure, on-premises systems where proprietary trading...
09 avr. 2026 16h01 HE | Source: Cardiff Oncology, Inc.

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief...
09 avr. 2026 09h00 HE | Source: Equity Insider

The Critical Minerals Nobody's Talking About Just Got a Federal Policy Boost

VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- EquityInsider.com Sector Commentary — Canada just committed over $3.6 billion to fast-track critical minerals projects at the world's...
09 avr. 2026 08h12 HE | Source: Sparian Biosciences, Inc

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NIH Grant

Sparian Biosciences initiates a phase 1 clinical trial of SBS-147, its next generation arylepoxamide receptor (AEAr) agonist for acute and chronic pain.
09 avr. 2026 08h00 HE | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for...

Page précédente

Page suivante